Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

Atara shares soar on positive tab-cel study results

By   /   Monday, December 9th, 2019  /   Comments Off on Atara shares soar on positive tab-cel study results

    Print       Email
Atara Biotherapeutics stock popped nearly 5 percent Dec. 9 on promising safety and efficacy data for its flagship drug tab-cel. In a study of 61 patients with disorders related to Epstein Barr Virus, the drug had high overall response and survival rates, Atara said in a news release. The Thousand Oaks company is working to…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Limoneira, Calavo both report earnings growth as produce industry continues recovery

Read More →